JAB-2485 not checked
Jacobio Pharmaceuticals Co., Ltd.
FollowEvery change as it happens, and a Monday email
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Solid Tumors, ER+ Breast Cancer, Triple Negative Breast Cancer, TNBC, ARID1A Gene Mutation, Small Cell Lung Cancer, SCLC
- Main trialPhase 1/2
- “This study is to evaluate the safety and tolerability of JAB-2485 monotherapy in adult participants with advanced solid tumors.”In the company’s words, NCT05490472 on ClinicalTrials.gov
Other drugs for Solid Tumors
- AvelumabEMD Serono Research & Development Institute, Inc. · Phase 3
- AlectinibRoche · Phase 3
- AtezolizumabRoche · Phase 3
- AU-011Aura Biosciences · Phase 3
- BevacizumabRoche · Phase 3
- CadonilimabAkeso · Phase 3
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1/2Recruiting | Aug 2026 | JAB-2485 Activity in Adult Patients With Advanced Solid Tumors |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 20 Nov 2026 · EU trials register (CTIS) updated 20 Nov 2026 · openFDA updated 20 Nov 2026